3 Fundamentally Strong Medical Devices Stocks in India
- August 21, 2026
- Posted by: Kunal Singla
- Category: Market
Medical Devices sector stocks. Poly Medicure Ltd CMP Rs 1771.63 | PE 57.39 | ROE 10.37%. Abbott India Ltd PE 34.74 | ROE 32.51%. Syngene International Ltd PE 54.00.
Quick Answer
Three medical devices stocks in India are Poly Medicure Ltd (MCap Rs 17,957 Cr, PE 57.39, ROE 10.37%), Abbott India Ltd (MCap Rs 56,100 Cr, PE 34.74, ROE 32.51%), and Syngene International Ltd (MCap Rs 15,500 Cr, PE 54.00, ROE 14.50%). Each covers a distinct sub-segment of the medical devices sector with different risk-reward profiles. Verify all data at nseindia.com or bseindia.com before making any investment decision.
Identifying the right medical devices stocks in India requires looking beyond short-term price movements and focusing on balance sheet strength, earnings consistency and sector positioning. Track the Nifty Pharma index alongside individual stock analysis for a complete picture of medical devices sector momentum.
This article covers three medical devices stocks in India with their key financial metrics. All figures are sourced from publicly available exchange disclosures. Verify every data point at nseindia.com or bseindia.com before making any investment decision.
Click Here – Get Free Investment Predictions
What Are Medical Devices Stocks in India?
Medical devices and healthcare research stocks in India are shares of companies that manufacture or distribute disposable medical devices, pharmaceuticals and contract research and manufacturing services. The medical device sector has been growing with India’s expanding healthcare infrastructure and rising surgical procedure volumes.
Budget 2026-27 Impact on Medical Devices Stocks in India
The Union Budget 2026-27 shaped the investment environment for medical devices stocks in India through the following provisions:
- PLI for medical devices and implants supports domestic production of catheters, stents and orthopedic implants.
- AIIMS and government hospital expansion drives procurement of medical consumables from domestic manufacturers.
- Health technology assessment framework improves reimbursement visibility for innovative medical devices.
- Ayushman Bharat PM-JAY coverage drives procedure volumes and indirectly increases disposable medical device consumption.
- Medical device quality standards tightening under CDSCO creates compliance barriers that benefit established manufacturers.
3 Fundamentally Strong Medical Devices Stocks in India: Key Data
| Company | CMP (Rs) | MCap (Rs Cr) | PE | PB | ROE | EPS TTM (Rs) | Div. Yield |
|---|---|---|---|---|---|---|---|
| Poly Medicure Ltd (NSE: POLYMED) | Rs 1771.63 | 17,957 | 57.39 | 5.78 | 10.37% | 30.87 | 0.20% |
| Abbott India Ltd (NSE: ABBOTINDIA) | Rs 26397.19 | 56,100 | 34.74 | 11.75 | 32.51% | 759.85 | 2.48% |
| Syngene International Ltd (NSE: SYNGENE) | Rs 1593.0 | 15,500 | 54.00 | 7.80 | 14.50% | 29.50 | 0.20% |
Data sourced from publicly available exchange filings. Verify all figures at nseindia.com before investing.
1. Poly Medicure Ltd (NSE: POLYMED)
Poly Medicure Ltd was founded in 1995 and is headquartered in Faridabad. It is one of three medical devices stocks in India covered in this article and trades at Rs 1771.63, with a market capitalisation of Rs 17,957 crore. The PE ratio stands at 57.39 against an industry average of 64.62, return on equity is 10.37%, EPS (TTM) Rs 30.87 and book value Rs 306.45. Dividend yield is 0.20%.
The company carries a debt-to-equity of 0.11 and price-to-book of 5.78. Investors should verify all figures directly at nseindia.com or bseindia.com before making any investment decision related to this or any other stock.
2. Abbott India Ltd (NSE: ABBOTINDIA)
Abbott India Ltd was founded in 1944 and is headquartered in Mumbai. It is one of three medical devices stocks in India covered in this article and trades at Rs 26397.19, with a market capitalisation of Rs 56,100 crore. The PE ratio stands at 34.74 against an industry average of 50.49, return on equity is 32.51%, EPS (TTM) Rs 759.85 and book value Rs 2246.68. Dividend yield is 2.48%.
The company carries a debt-to-equity of 0.04 and price-to-book of 11.75. Investors should verify all figures directly at nseindia.com or bseindia.com before making any investment decision related to this or any other stock.
Compare Medical Devices Stocks by PE, ROE and Dividend Yield on the Univest Screener
3. Syngene International Ltd (NSE: SYNGENE)
Syngene International Ltd was founded in 1993 and is headquartered in Bengaluru. It is one of three medical devices stocks in India covered in this article and trades at Rs 1593.0, with a market capitalisation of Rs 15,500 crore. The PE ratio stands at 54.00 against an industry average of 50.49, return on equity is 14.50%, EPS (TTM) Rs 29.50 and book value Rs 200.00. Dividend yield is 0.20%.
The company carries a debt-to-equity of 0.15 and price-to-book of 7.80. Investors should verify all figures directly at nseindia.com or bseindia.com before making any investment decision related to this or any other stock.
Download the Univest iOS App or Univest Android App to track these medical devices stocks in India with live prices and exchange-sourced research.
Factors That Affect Medical Devices Stocks in India
- Interest rate environment: RBI policy changes affect cost of capital and consumer demand relevant to medical devices companies.
- Government capex: Budget allocations shape order books and revenue visibility for medical devices stocks in India.
- Input cost movements: Raw material inflation or deflation affects operating margins for medical devices stocks in India within a single quarter.
- FII and DII flows: Institutional buying and selling creates short-term price volatility that may not reflect underlying fundamentals of medical devices stocks in India.
- Global sector trends: Technology shifts, export demand changes and competitive dynamics influence long-term earnings of medical devices stocks in India.
Benefits of Investing in Fundamentally Strong Medical Devices Stocks
- Earnings consistency: medical devices stocks in India with strong fundamentals across PE, ROE and EPS metrics have historically delivered more predictable earnings growth than low-quality peers.
- Lower downside risk: Fundamentally strong medical devices stocks in India with manageable debt and positive free cash flow tend to recover faster from market corrections than highly leveraged peers.
- Dividend income potential: Several medical devices stocks in India with strong fundamentals maintain consistent dividend track records, adding an income layer alongside capital appreciation.
- Index inclusion benefits: Large-cap medical devices stocks in India included in major indices receive mandatory passive investment flows from index funds and ETFs.
- Regulatory advantage: Established medical devices stocks in India with clean governance records have easier access to capital markets and face lower regulatory disruption risk.
Risks of Investing in Medical Devices Stocks
- Sector cyclicality: Medical Devices stocks can experience multi-quarter earnings pressure during economic downturns or policy headwinds. medical devices stocks in India are not immune to sector-level cycles.
- Valuation compression: High-PE medical devices stocks in India can de-rate sharply when earnings miss expectations or when sector sentiment turns negative.
- Competition risk: Domestic and international competition can erode market share or pricing power for even fundamentally strong medical devices stocks in India over time.
- Regulatory changes: Policy shifts in taxation, import duties or sector regulation can affect profitability of medical devices stocks in India with limited advance warning.
- Execution risk: For project-based medical devices stocks in India, delayed execution or working capital pressure can affect quarterly earnings significantly.
How to Choose Fundamentally Strong Medical Devices Stocks
- Screen for PE ratios in line with or below the sector average; any premium PE among medical devices stocks in India requires earnings growth justification
- Target ROE consistently above 12% for at least three consecutive years to confirm durable profitability
- Check debt-to-equity below 1 for most medical devices stocks in India and below 2 for capital-intensive or financial medical devices stocks in India
- Verify dividend payment history as a signal of management’s confidence in free cash flow generation
- Cross-reference with the latest quarterly results to confirm fundamentals are moving in the right direction
Conclusion
Poly Medicure Ltd, Abbott India Ltd and Syngene International Ltd are three medical devices stocks in India representing distinct positioning within the medical devices sector. Poly Medicure Ltd trades at Rs 1771.63 with PE 57.39 and ROE 10.37%; Abbott India Ltd at Rs 26397.19 with PE 34.74; and Syngene International Ltd at Rs 1593.0 with PE 54.00. Each of these medical devices stocks in India carries distinct risks requiring individual evaluation. This article is for educational purposes only. Consult a SEBI-registered financial advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs
What does Poly Medicure make?
Ans. Poly Medicure is a manufacturer of disposable medical devices including IV cannulas, blood transfusion sets, infusion sets and urological catheters. It exports approximately 60-65% of its production to developed markets.
Is Abbott India a pharmaceutical or medical device company?
Ans. Abbott India is primarily a pharmaceutical company selling branded generics and specialty products in India. It distributes products from its global parent Abbott Laboratories. Its strong ROE of 32.51% reflects the branded pharma business model.
What does Syngene International do?
Ans. Syngene International is a contract research and manufacturing organisation (CRMO) that provides drug discovery, development and manufacturing services to global pharmaceutical and biotech companies. It is a Biocon subsidiary.
